Reply: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management
- PMID: 36896969
- DOI: 10.1097/HEP.0000000000000358
Reply: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management
Comment on
-
Letter to the Editor: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.Hepatology. 2024 Jan 1;79(1):E1-E2. doi: 10.1097/HEP.0000000000000359. Epub 2023 Mar 30. Hepatology. 2024. PMID: 36988390 No abstract available.
References
-
- Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatology. 2023 . doi:10.1097/HEP.0000000000000291. - DOI
-
- Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int. 2015;35:2009–16.
-
- Udumyan R, Montgomery S, Duberg AS, Fang F, Valdimarsdottir U, Ekbom A, et al. Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. Scand J Gastroenterol. 2020;55:597–605.
-
- Franchis RDE, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.
-
- Tripathi D, Reiberger T. Letter to the Editor: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management. Hepatology. 2023. doi:10.1097/HEP.0000000000000359. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
